ESPE Abstracts (2019) 92 P3-141

Treatment Outcome of Growth Hormone in Turner Syndrome Children

Bui Phuong Thao1, Vu Chi Dung1, Pham Thi Nhu Hoa2, Nguyen Ngoc Khanh1, Can Thi Bich Ngoc1, Do Thi Thanh Mai1, Nguyen Thu Ha1


1National Children's Hospital, Hanoi, Vietnam. 2Thanh Nhan Hospital, Hanoi, Vietnam


Background: Turner syndrome (TS) patients frequently have short stature. Females adults with TS are usually 20 cm shorter than normal females. Growth hormone (GH) can improve final height in TS patients.

Objective: To evaluate GH therapy for children with Turner syndrome in term of efficacy and side effect

Patient and Method: This serial cases study was done in TS patients in a period August 2018 to April 2019. Patients were enrolled if they had at least 1 year of GH treatment. The patients were diagnosed and treated in Vietnam National Children's Hospital. GH was indicated in TS patients when height was less than – 2SD according to WHO 2007. The starting dose of GH was 0.05 mg/kg/day.

Results: In our study 49 TS patients were enrolled: 19 patients with 45,X (38.8%); 15 TS patients with mosaics (30.6%); 15 patients with structural abnormalities (30.6). Mean age at study time was 8.2 ± 3,5 (Min = 1; Max = 15). Patients' height before treatment was 110.5±15.5 cm. Patients' height 1 year, 2 year, 3 year, 4 year after GH treatment were 117.5±14.9 cm; 119.9±24.9 cm; 127.8±13.8 cm; 130.2±13.9 cm, respectively.

In patients aged < 5 years, height SD score was (-2.98) ± (-1.87) before GH treatment (n=9); (-2.33) ± (-1.77) 1 year after treatment (n=9); (-2.00) ± (-1.66) 2 years after treatment (n=6); (-1.53) ± (-0.78) 3 years after treatment (n=4).

In patients aged from 5 to < 10 years, height SD score was (-3.44) ± (-2.13) before GH treatment (n=20); (3.02) ± (-1.98) 1 year after treatment (n=19); (-2,22) ± (-1,30)2 years after treatment (n=7); (-2,78) ± (-1,00) 3 years after treatment (n=4).

In patients aged from 10 to 15 years, height SD score was (-2,67) ± (-2,00) before GH treatment (n=20); (-2,58) ± (-1,73) 1 year after treatment (n=20); (-2,00) ± (-0,67) 2 years after treatment (n=12); (-1,89) ± (-1,11) 3 years after treatment (n=6).

In term of side effect, 12.2% patients had headache during treatment; 2% patients had arthralgia. These side effect were mild and transient.

Conclusion: GH treatment was effective in increasing height SD score in TS patients.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts